Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.  This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).  The current trial represents the seventh clinical study of Quark synthetic siRNAs.  QPI-1007 has been evaluated in several preclinical models of ocular neuroprotection, and has been shown in these models to protect retinal ganglion cells from injury-induced apoptosis.

The study is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug will be given to all patients who participate.  This study will determine whether QPI-1007 is safe when it is injected into the eye and will also reveal if there are any side effects of the drug and how long it takes for the body to clear the drug.  In addition, the study will examine the biological activity of the drug in NAION patients.  The study will enroll patients in two strata, and is being conducted in the U.S. and Israel.  Stratum I will enroll legally blind patients, while stratum II will enroll patients with recent onset of NAION.

Shai Erlich, Ph.D., Chief Medical Officer of Quark, commented, "Based on the pre-clinical results we've seen for QPI-1007, we are pleased to initiate dosing in human clinical trials. QPI-1007 is a siRNA molecule with Quark's proprietary structure and its entry into clinical trials reflects the Company's success in developing novel siRNA compounds.  These accomplishments further validate Quark's ability to advance innovative product candidates from discovery into the clinic."

Dr. Daniel Zurr, Quark's Chief Executive Officer, said, "The initiation of dosing in this trial brings the total number of siRNA programs in the clinic to five, an unprecedented number in the RNAi industry.  Beyond the size of our clinical stage siRNA portfolio, we are proud that this particular product, QPI-1007, was developed using entirely independent structural IP, further demonstrating our leadership in the field."

QPI-1007 is Quark's first siRNA drug candidate to utilize intellectual property developed internally in collaboration with BioSpring GmbH, and gives Quark freedom to operate in the siRNA IP space.  Preclinical studies have demonstrated a robust neuroprotective effect of QPI-1007 when administered immediately after injury induced by optic nerve crush or axotomy in two models of retinal ganglion cell (RGC) death as well as in a rat intraocular pressure (IOP) elevation model in which the drug was injected 2 weeks after IOP elevating operation.

Source:

Quark Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Celiac disease may now be curable with biodegradable nanoparticles